2021 IEEE International Conference on Bioinformatics and Biomedicine (BIBM),
Journal Year:
2022,
Volume and Issue:
unknown, P. 749 - 752
Published: Dec. 6, 2022
Despite
the
advancement
in
management
of
prostate
cancer
recent
years,
treatment
strategies
are
only
efficient
against
localized
disease
while
managing
metastatic
remains
a
challenge.
As
result,
global
burden
has
remained
significant.
Efficient
and
personalized
before
metastasis
is
therefore
prime
importance.
In
this
study,
we
developed
classifier
to
predict
response
patients
leveraging
on
multi-omics
datasets
provided
by
The
Cancer
Genome
Atlas
(TCGA).
Our
investigation
using
ten
machine
learning
algorithms
reveals
that
tree-based
had
better
predictive
performance
than
probabilistic
models
such
as
Naive
Bayes
kernel-based
methods
Support
Vector
Machines.
We
also
investigated
all
possible
omics
combinations.
results
show
there
an
overall
increase
when
multiple
used
contrast
single
strategies.
have
predicted
for
first
time,
androgen
deprivation
outcomes
68
with
missing
phenotype
values
TCGA
dataset.
Cancers,
Journal Year:
2023,
Volume and Issue:
15(16), P. 4164 - 4164
Published: Aug. 18, 2023
Breast
cancer
continues
to
pose
a
significant
healthcare
challenge
worldwide
for
its
inherent
molecular
heterogeneity.
This
review
offers
an
in-depth
assessment
of
the
profiling
undertaken
understand
this
heterogeneity,
focusing
on
multi-omics
strategies
applied
both
in
traditional
bulk
and
single-cell
levels.
Genomic
investigations
have
profoundly
informed
our
comprehension
breast
cancer,
enabling
categorization
into
six
intrinsic
subtypes.
Beyond
genomics,
transcriptomics
has
rendered
deeper
insights
gene
expression
landscape
cells.
It
also
facilitated
formulation
more
precise
predictive
prognostic
models,
thereby
enriching
field
personalized
medicine
cancer.
The
comparison
between
identified
unique
patterns
understanding
cell-to-cell
variability.
Proteomics
provides
further
subtypes
by
illuminating
intricate
protein
their
post-translational
modifications.
adoption
proteomics
been
instrumental
regard,
revealing
complex
dynamics
regulation
interaction.
Despite
these
advancements,
underscores
need
holistic
integration
multiple
‘omics’
fully
decipher
Such
not
only
ensures
comprehensive
cancer’s
complexities,
but
promotes
development
treatment
strategies.
International Journal of Molecular Sciences,
Journal Year:
2023,
Volume and Issue:
24(3), P. 2289 - 2289
Published: Jan. 24, 2023
The
reduction
in
androgen
synthesis
and
the
blockade
of
receptor
(AR)
function
by
chemical
castration
AR
signaling
inhibitors
represent
main
treatment
lines
for
initial
stages
prostate
cancer.
Unfortunately,
resistance
mechanisms
ultimately
develop
due
to
alterations
pathway,
such
as
gene
amplification
or
mutations,
also
emergence
alternative
pathways
that
render
tumor
less
or,
more
rarely,
completely
independent
activation.
An
essential
oncogenic
axis
activated
cancer
is
phosphatidylinositol-3-kinase
(PI3K)/AKT/mammalian
target
rapamycin
(mTOR)
evidenced
frequent
negative
regulator
phosphatase
tensin
homolog
(PTEN)
activating
mutations
PI3K
subunits.
Additionally,
crosstalk
reciprocal
feedback
loops
between
PI3K/AKT/mTOR
cascade
activate
pro-survival
signals
play
an
role
disease
recurrence
progression
have
been
evidenced.
Inhibitors
addressing
different
players
pathway
evaluated
clinic.
Only
a
limited
benefit
has
reported
up
now
associated
side
effects,
so
novel
combination
approaches
biomarkers
predictive
patient
response
are
urgently
needed.
Here,
we
reviewed
recent
data
on
selective
identified,
most
advanced
clinical
studies,
with
focus
treatments.
A
deeper
understanding
complex
molecular
involved
further
guide
therapeutic
improved
outcomes.
Frontiers in Oncology,
Journal Year:
2025,
Volume and Issue:
15
Published: Feb. 11, 2025
Prostate
cancer
is
the
most
common
among
men
worldwide,
especially
in
those
over
65,
and
a
leading
cause
of
cancer-related
mortality.
The
disease
typically
advances
from
an
androgen-dependent
state
to
castration-resistant
prostate
(CRPC),
which
poses
significant
treatment
challenges.
androgen
receptor
(AR)
on
X
chromosome
central
driver
this
process,
activating
genes
that
govern
proliferation
survival.
Mutations
amplifications
AR
are
closely
associated
with
progression
resistance.
While
traditional
therapies
such
as
deprivation
therapy
(ADT)
antagonists
like
enzalutamide
have
been
effective,
resistance
persists
due
reactivation
signaling
through
mechanisms
ligand-independent
activation.
Recent
research
highlights
role
epigenetic
modifications
enhancing
activity
drug
tumor
microenvironment,
particularly
interactions
cancer-associated
fibroblasts
(CAFs)
tumor-associated
macrophages
(TAMs),
further
complicates
by
promoting
aggressive
behavior
immune
evasion.
Future
directions
include
developing
next-generation
antagonists,
identifying
AR-related
biomarkers
for
personalized
therapy,
exploring
combinations
checkpoint
inhibitors.
Additionally,
basal
cell-lumen-derived
organoids
provide
innovative
models
can
enhance
understanding
strategies
cancer.
Frontiers in Cardiovascular Medicine,
Journal Year:
2023,
Volume and Issue:
10
Published: Oct. 30, 2023
Myocardial
infarction
(MI)
is
a
prevalent
cardiovascular
disease
characterized
by
myocardial
necrosis
resulting
from
coronary
artery
ischemia
and
hypoxia,
which
can
lead
to
severe
complications
such
as
arrhythmia,
cardiac
rupture,
heart
failure,
sudden
death.
Despite
being
research
hotspot,
the
etiological
mechanism
of
MI
remains
unclear.
The
emergence
widespread
use
omics
technologies,
including
genomics,
transcriptomics,
proteomics,
metabolomics,
other
omics,
have
provided
new
opportunities
for
exploring
molecular
identifying
large
number
biomarkers.
However,
single-omics
approach
has
limitations
in
understanding
complex
biological
pathways
diseases.
multi-omics
reveal
interaction
network
among
molecules
at
various
levels
overcome
approaches.
This
review
focuses
on
studies
MI,
epigenomics,
omics.
exploration
extended
into
domain
integrative
analysis,
accompanied
compilation
diverse
online
resources,
databases,
tools
conducive
these
investigations.
Additionally,
we
discussed
role
prospects
approaches
personalized
medicine,
highlighting
potential
improving
diagnosis,
treatment,
prognosis
MI.
Cyborg and Bionic Systems,
Journal Year:
2024,
Volume and Issue:
5
Published: Jan. 1, 2024
Prostate
cancer
is
one
of
the
most
prevalent
malignant
tumors
in
men
worldwide,
and
early
diagnosis
essential
to
improve
patient
survival.
This
review
provides
a
comprehensive
discussion
recent
advances
prostate
biomarkers,
including
molecular,
cellular,
exosomal
biomarkers.
The
potential
various
biomarkers
such
as
gene
fusions
(TMPRSS2-ERG),
noncoding
RNAs
(SNHG12),
proteins
(PSA,
PSMA,
AR),
circulating
tumor
cells
(CTCs)
diagnosis,
prognosis,
targeted
therapies
emphasized.
In
addition,
this
systematically
explores
how
multi-omics
data
artificial
intelligence
technologies
can
be
used
for
biomarker
discovery
personalized
medicine
applications.
insights
into
development
specific
probes,
fluorescent,
electrochemical,
radionuclide
sensitive
accurate
detection
conclusion,
overview
status
future
directions
research,
emphasizing
precision
therapy.
